Q3 2024 EPS Estimates for Indivior PLC (NASDAQ:INDV) Reduced by Northland Capmk

Indivior PLC (NASDAQ:INDVFree Report) – Investment analysts at Northland Capmk cut their Q3 2024 earnings per share (EPS) estimates for Indivior in a research note issued on Tuesday, July 9th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings per share of $0.40 for the quarter, down from their prior forecast of $0.43. The consensus estimate for Indivior’s current full-year earnings is $1.93 per share. Northland Capmk also issued estimates for Indivior’s Q4 2024 earnings at $0.44 EPS and FY2024 earnings at $1.55 EPS.

Separately, Craig Hallum decreased their target price on Indivior from $37.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday.

Read Our Latest Report on INDV

Indivior Stock Up 3.1 %

Shares of INDV opened at $10.51 on Thursday. The company has a market cap of $1.45 billion, a PE ratio of 1,051.00 and a beta of 0.69. The business has a fifty day moving average of $16.68 and a 200 day moving average of $18.01. Indivior has a 52-week low of $9.14 and a 52-week high of $24.90. The company has a quick ratio of 0.74, a current ratio of 0.92 and a debt-to-equity ratio of 23.50.

Indivior (NASDAQ:INDVGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.01). The company had revenue of $284.00 million during the quarter, compared to the consensus estimate of $300.00 million. Indivior had a return on equity of 842.72% and a net margin of 0.44%.

Institutional Trading of Indivior

Several institutional investors and hedge funds have recently made changes to their positions in the business. Campbell & CO Investment Adviser LLC lifted its position in shares of Indivior by 2.8% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock worth $573,000 after purchasing an additional 1,037 shares during the last quarter. Renaissance Group LLC raised its holdings in shares of Indivior by 6.1% in the fourth quarter. Renaissance Group LLC now owns 103,023 shares of the company’s stock valued at $1,573,000 after acquiring an additional 5,896 shares in the last quarter. Chilton Investment Co. Inc. bought a new stake in shares of Indivior in the fourth quarter valued at about $263,000. ADAR1 Capital Management LLC bought a new stake in shares of Indivior in the fourth quarter valued at about $368,000. Finally, Royal London Asset Management Ltd. raised its holdings in shares of Indivior by 5.8% in the fourth quarter. Royal London Asset Management Ltd. now owns 447,828 shares of the company’s stock valued at $6,838,000 after acquiring an additional 24,383 shares in the last quarter. 60.33% of the stock is currently owned by institutional investors.

About Indivior

(Get Free Report)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

See Also

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.